TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04137003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rouge et Or Program
Description: It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
Study: NCT01783574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02029183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi level positive pressure ventilation
Description: Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
Study: NCT04137003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHU intervention guide
Description: From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
Study: NCT04464512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: IV buprenorphine plus IV sufentanil treatment group.
Study: NCT03349112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4% Lidocaine Spray
Description: 2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2% Viscous Lidocaine
Description: 2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 2% Viscous Lidocaine
Description: 2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
Study: NCT02485301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administrated intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Description: A single dose administrated intramuscular

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose administrated intramuscular
Study: NCT00157950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil™
Description: Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
Study: NCT02029183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bi-level positive airway pressure
Study: NCT00269282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Training
Description: Asthma education and self-monitoring strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Training
Description: Asthma education and self-monitoring strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
Study: NCT03589950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib plus chemotherapy
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
Study: NCT02994953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
Study: NCT03589950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
Study: NCT01529346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
Study: NCT00386776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-based medical history
Description: The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
Study: NCT01705899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Pancreatic Islets
Description: Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Pancreatic Islets
Description: Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
Study: NCT01610947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, Etanercept, Golimumab or infliximab
Description: Continuation of usual treatment with fixed intervals according to standard recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, Etanercept, Golimumab or infliximab
Description: Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
Study: NCT03454581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Description: Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Description: Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
Study: NCT03989557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel/Ticagrelor
Description: The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light transmittance aggregometry
Description: point-of-care method to assess platelet function by light transmittance aggregometry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel/Ticagrelor
Description: maintenance dose of aspirin, clopidogrel and ticagrelor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel/Ticagrelor
Description: maintenance dose of aspirin, clopidogrel and ticagrelor.
Study: NCT01524510

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: low dose radiation scan without contrast without and with MRA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alice PDx polygraphy
Description: Alice PDx polygraphy (Respironics)
Study: NCT02335489

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study: NCT04190615

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastometry test (TEM test)
Description: TEM test from the whole blood sample
Study: NCT04563689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)
Description: rinse 15 ml during 1 min during 5 days, twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo rinse
Description: destilled water rinse 15 ml during 1 min during 5 days, twice daily
Study: NCT02859779

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education programs
Description: Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
Study: NCT03036761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: 3 sessions of auriculotherapy at one month intervals.
Study: NCT04120831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept Injection
Description: Drug
Study: NCT04700982

Intervention type: OTHER
Intervention: Based on the length of hospital stay
Description: Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
Study: NCT02311010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: daily dose adapted according to Cyp 3A5 polymorphism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: daily dose adapted according to Cyp 3A5 polymorphism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: daily dose adapted according to Cyp 3A5 polymorphism
Study: NCT00549302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
Study: NCT02890589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY stent
Description: Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)
Description: Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations.
Study: NCT00834860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alpha-2a and ribavirin
Description: They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alpha-2a and ribavirin
Description: They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
Study: NCT02986789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In vivo SpHb and PVi Monitoring
Description: Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
Study: NCT03887286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips EPIQ 7 ultrasound machine
Description: Standard transthoracic echocardiography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Lumify Broadband sector array transducer
Description: Portable hand-held ultrasound device
Study: NCT00682409

Intervention type: OTHER
Group type: OTHER
Intervention: MR Imaging
Description: MR imaging in the post operative follow-up of cholesteatoma in children
Study: NCT04599660

Intervention type: OTHER
Intervention: Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)
Description: This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
Study: NCT04108598

Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: No intervention will be administered, select sites will administer a quality of life questionnaire
Study: NCT06071533

Intervention type: DRUG
Intervention: Dandshen
Description: Dandshen injection 20ml /day
Study: NCT00670813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil (Vigil)
Description: Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
Study: NCT00369564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamic acid
Description: Given orally 3 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally 3 times daily
Study: NCT03174392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Based Training
Description: Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speed Based Training
Description: Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
Study: NCT01861015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Study: NCT02599025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innowalk cycling system
Description: Innowalk is a unique, motorized medical device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APT cycling system
Description: APT is used as a rehabilitative device that cycles the feet automatically or by the individual
Study: NCT01972776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076
Description: Supplied in 25 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076
Description: Supplied in 25 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076
Description: Supplied in 25 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076
Description: Supplied in 25 mg and 75 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT01580306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: Relevant treatment dose capsule (A) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: Relevant treatment dose capsule (B) for oral administration
Study: NCT04262115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AM-EX
Description: AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
Study: NCT02994953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (Once weekly)
Description: Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (Once weekly)
Description: Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
Study: NCT04262115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM-EX
Description: PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.